CO6220840A2 - Formulaciones para el tratamiento de cancer - Google Patents
Formulaciones para el tratamiento de cancerInfo
- Publication number
- CO6220840A2 CO6220840A2 CO09085583A CO09085583A CO6220840A2 CO 6220840 A2 CO6220840 A2 CO 6220840A2 CO 09085583 A CO09085583 A CO 09085583A CO 09085583 A CO09085583 A CO 09085583A CO 6220840 A2 CO6220840 A2 CO 6220840A2
- Authority
- CO
- Colombia
- Prior art keywords
- solubility
- compound
- pharmaceutical composition
- formula
- pure water
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona composiciones, kits y métodos para uso en el tratamiento de cánceres y afecciones víricas. En particular, la invención proporciona composiciones farmacéuticas que contienen compuestos de nitrobenzamida que tienen mayor solubilidad en soluciones acuosas. 1.- Una composición farmacéutica que comprende un compuesto de fórmula (la)en la que R1, R2, R3, R4 y R5 se seleccionan independientemente entre el grupo que consiste en hidrógeno, hidroxi, amino, nitro, yodo, bromo, flúor, cloro, alquilo (C1-C6), alcoxi (C1-C6), cicloalquilo (C3-C7) y fenilo, donde al menos dos de los cinco sustituyentes R1, R2, R3, R4 y R5 son siempre hidrógeno, al menos uno de los cinco sustituyentes es siempre nitro, y al menos un sustituyente situado adyacente a un nitro es siempre yodo, y sales farmacéuticamente aceptables, solvatos, isómeros, tautómeros, metabolitos, análogos o profármacos del mismo, y al menos un solubilizante farmacéuticamente aceptable. 2.- La composición farmacéutica de la reivindicación 1, donde el solubilizante comprende una ciclodextrina, un tensioactivo, un codisolvente o mezclas de dos o más de los mismos. 3.- La composición farmacéutica de la reivindicación 1, donde la solubilidad del compuesto de fórmula la es al menos aproximadamente 1,5 veces a solubilidad del compuesto en agua pura. 4.- La composición farmacéutica de la reivindicación 1, donde la solubilidad del compuesto de fórmula la es al menos aproximadamente 2 veces la solubilidad del compuesto en agua pura. 5.- La composición farmacéutica de la reivindicación 1, donde la solubilidad del compuesto de fórmula la es al menos aproximadamente 5 veces la solubilidad del compuesto en agua pura. 6.- La composición farmacéutica de la reivindicación 1, donde la solubilidad del compuesto de fórmula la es al menos aproximadamente 10 veces la solubilidad del compuesto en agua pura. 7.- La composición farmacéutica de la reivindicación 1, donde la solubilidad del compuesto de fórmula la es al menos aproximadamente 50 veces la solubilidad del compuesto en agua pura.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88075507P | 2007-01-16 | 2007-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6220840A2 true CO6220840A2 (es) | 2010-11-19 |
Family
ID=39350967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09085583A CO6220840A2 (es) | 2007-01-16 | 2009-08-14 | Formulaciones para el tratamiento de cancer |
Country Status (33)
Country | Link |
---|---|
US (1) | US20080176946A1 (es) |
EP (2) | EP2121139B1 (es) |
JP (1) | JP2010516626A (es) |
KR (1) | KR20090113852A (es) |
CN (1) | CN101668561A (es) |
AU (1) | AU2008206294A1 (es) |
BR (1) | BRPI0806590A2 (es) |
CA (1) | CA2674600A1 (es) |
CO (1) | CO6220840A2 (es) |
CR (1) | CR10975A (es) |
CY (1) | CY1113819T1 (es) |
DK (1) | DK2121139T3 (es) |
DO (1) | DOP2009000178A (es) |
EC (1) | ECSP099577A (es) |
ES (1) | ES2395690T3 (es) |
GB (1) | GB2447796C (es) |
GT (1) | GT200900201A (es) |
HK (2) | HK1121697A1 (es) |
HR (1) | HRP20120960T1 (es) |
IL (1) | IL199682A0 (es) |
MA (1) | MA34559B1 (es) |
MX (1) | MX2009007596A (es) |
NZ (1) | NZ579098A (es) |
PL (1) | PL2121139T3 (es) |
PT (1) | PT2121139E (es) |
RS (1) | RS52633B (es) |
RU (2) | RU2481830C2 (es) |
SG (1) | SG178714A1 (es) |
SI (1) | SI2121139T1 (es) |
SV (1) | SV2009003335A (es) |
TN (1) | TN2009000292A1 (es) |
UA (1) | UA100852C2 (es) |
WO (1) | WO2008089272A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7961081B2 (en) * | 2003-05-22 | 2011-06-14 | John Tomlienovic | Anti-theft system and method |
AU2006257815A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | PARP modulators and treatment of cancer |
SG164368A1 (en) | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
JP2010504079A (ja) * | 2006-06-12 | 2010-02-12 | バイパー サイエンシズ,インコーポレイティド | Parp阻害剤を用いる疾病の治療方法 |
US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
CA2662337A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
US20090149417A1 (en) * | 2007-10-19 | 2009-06-11 | Valeria Ossovskaya | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors |
SG185952A1 (en) | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
CN101999002A (zh) * | 2008-02-04 | 2011-03-30 | 彼帕科学公司 | 诊断和治疗parp-介导的疾病的方法 |
US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
WO2010036226A1 (en) * | 2008-09-26 | 2010-04-01 | George Nelson | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
US20110020392A1 (en) * | 2008-10-14 | 2011-01-27 | Salubrious Pharmaceutical, Llc | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
CA2833914A1 (en) * | 2011-05-10 | 2012-11-15 | Universite Laval | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
MY170427A (en) * | 2012-11-30 | 2019-07-31 | Glaxosmithkline Llc | Novel pharmaceutical composition |
WO2017192618A1 (en) * | 2016-05-02 | 2017-11-09 | Symbios Technologies, Inc. | Electrochemical plasma activated aqueous chemotherapeutics |
EP3655418A4 (en) | 2017-06-22 | 2021-05-19 | Triact Therapeutics, Inc. | METHOD OF TREATMENT OF GLIOBLASTOMA |
EA202090573A1 (ru) | 2017-09-26 | 2020-09-07 | Тесаро, Инк. | Составы нирапариба |
US11628144B2 (en) | 2017-09-29 | 2023-04-18 | Triact Therapeutics, Inc. | Iniparib formulations and uses thereof |
WO2020246737A1 (ko) * | 2019-06-04 | 2020-12-10 | 사회복지법인 삼성생명공익재단 | 콰시노이드를 포함하는 거세 저항성 전립선암 치료용 조성물 |
CZ309587B6 (cs) * | 2021-01-22 | 2023-05-03 | Oncora S.R.O. | Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy |
GB2611315B (en) * | 2021-09-29 | 2024-01-03 | Siemens Healthcare Gmbh | Method of operating a magnetic resonance scanner |
WO2023239919A1 (en) * | 2022-06-10 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0348655A (ja) * | 1989-07-14 | 1991-03-01 | Shionogi & Co Ltd | プロスタグランジンd↓2類の安定化 |
US5633282A (en) * | 1990-05-25 | 1997-05-27 | British Technology Group Limited | Inhibition of viral infection |
US5232735A (en) * | 1990-06-01 | 1993-08-03 | Bioresearch, Inc. | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers |
US5637618A (en) * | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5631038A (en) * | 1990-06-01 | 1997-05-20 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5484951A (en) * | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
US5877185A (en) * | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
US5482975A (en) * | 1991-10-22 | 1996-01-09 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
US5652260A (en) * | 1991-10-22 | 1997-07-29 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
US5516941A (en) * | 1991-10-22 | 1996-05-14 | Octamer, Inc. | Specific inactivators of "retroviral" (asymmetric) zinc fingers |
GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
US5558855A (en) | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US6015792A (en) * | 1993-05-26 | 2000-01-18 | Bioresearch, Inc. | Specific eatable taste modifiers |
US6008250A (en) * | 1993-05-26 | 1999-12-28 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
WO1996038175A1 (en) * | 1995-06-02 | 1996-12-05 | Takeda Chemical Industries, Ltd. | Stabilized composition comprising an antiulcerative benzimidazole |
US5837729A (en) * | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
AU7074298A (en) * | 1997-04-10 | 1998-10-30 | Foster, Robert T. | Activated iododerivatives for the treatment of cancer and aids |
US5908861A (en) * | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
US6696426B2 (en) * | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
MXPA03006071A (es) * | 2001-01-04 | 2004-02-26 | Daiichi Seiyaku Co | Preparaciones de ciclodextrina. |
US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
AU2004206844A1 (en) * | 2003-01-14 | 2004-08-05 | Teva Pharmaceutical Industries, Ltd. | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
AU2006257815A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | PARP modulators and treatment of cancer |
SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
JP2010504079A (ja) * | 2006-06-12 | 2010-02-12 | バイパー サイエンシズ,インコーポレイティド | Parp阻害剤を用いる疾病の治療方法 |
CA2662337A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
WO2008030883A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
WO2008030887A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
-
2008
- 2008-01-16 PL PL08727771T patent/PL2121139T3/pl unknown
- 2008-01-16 ES ES08727771T patent/ES2395690T3/es active Active
- 2008-01-16 PT PT87277711T patent/PT2121139E/pt unknown
- 2008-01-16 CA CA002674600A patent/CA2674600A1/en not_active Withdrawn
- 2008-01-16 DK DK08727771.1T patent/DK2121139T3/da active
- 2008-01-16 AU AU2008206294A patent/AU2008206294A1/en not_active Withdrawn
- 2008-01-16 JP JP2009545734A patent/JP2010516626A/ja not_active Withdrawn
- 2008-01-16 MX MX2009007596A patent/MX2009007596A/es active IP Right Grant
- 2008-01-16 GB GB0807263A patent/GB2447796C/en not_active Withdrawn - After Issue
- 2008-01-16 CN CN200880008617A patent/CN101668561A/zh active Pending
- 2008-01-16 BR BRPI0806590-0A patent/BRPI0806590A2/pt not_active Application Discontinuation
- 2008-01-16 EP EP08727771A patent/EP2121139B1/en active Active
- 2008-01-16 UA UAA200908564A patent/UA100852C2/ru unknown
- 2008-01-16 SI SI200830855T patent/SI2121139T1/sl unknown
- 2008-01-16 RS RS20120544A patent/RS52633B/en unknown
- 2008-01-16 SG SG2012003109A patent/SG178714A1/en unknown
- 2008-01-16 EP EP11192725A patent/EP2476461A3/en not_active Withdrawn
- 2008-01-16 KR KR1020097017060A patent/KR20090113852A/ko not_active Application Discontinuation
- 2008-01-16 NZ NZ579098A patent/NZ579098A/en not_active IP Right Cessation
- 2008-01-16 US US12/015,403 patent/US20080176946A1/en not_active Abandoned
- 2008-01-16 RU RU2009130599/15A patent/RU2481830C2/ru not_active IP Right Cessation
- 2008-01-16 WO PCT/US2008/051214 patent/WO2008089272A1/en active Application Filing
- 2008-01-16 MA MA32171A patent/MA34559B1/fr unknown
-
2009
- 2009-02-26 HK HK09101870.4A patent/HK1121697A1/xx not_active IP Right Cessation
- 2009-07-02 IL IL199682A patent/IL199682A0/en unknown
- 2009-07-07 TN TNP2009000292A patent/TN2009000292A1/fr unknown
- 2009-07-14 DO DO2009000178A patent/DOP2009000178A/es unknown
- 2009-07-15 GT GT200900201A patent/GT200900201A/es unknown
- 2009-07-15 SV SV2009003335A patent/SV2009003335A/es unknown
- 2009-08-13 EC EC2009009577A patent/ECSP099577A/es unknown
- 2009-08-14 CO CO09085583A patent/CO6220840A2/es not_active Application Discontinuation
- 2009-08-14 CR CR10975A patent/CR10975A/es unknown
-
2010
- 2010-05-24 HK HK10105011.2A patent/HK1137158A1/xx not_active IP Right Cessation
-
2012
- 2012-11-23 HR HRP20120960AT patent/HRP20120960T1/hr unknown
- 2012-12-03 RU RU2012151571/15A patent/RU2012151571A/ru unknown
-
2013
- 2013-01-09 CY CY20131100023T patent/CY1113819T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6220840A2 (es) | Formulaciones para el tratamiento de cancer | |
AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
CA2662517A1 (en) | Treatment of cancer | |
AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
SV2010003464A (es) | Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas | |
UY28821A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos. | |
AR058569A1 (es) | Inhibidores de histona desacetilasa para mejorar la actividad de agentes antifungicos | |
AR054341A1 (es) | Combinaciones sinergicas de compuestos activos fungicidas | |
AR048039A1 (es) | Profarmacos de piperazina y agentes antivirales de piperidina sustituidos | |
AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
CL2008003651A1 (es) | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. | |
AR076850A1 (es) | Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa. | |
PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
WO2007099162A3 (fr) | Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques | |
NI200800008A (es) | Métodos para la neuroprotección | |
AR065464A1 (es) | Derivados de nicotinamida. composiciones farmaceuticas | |
AR067770A1 (es) | Derivados de tiazol y ditiazol para el tratamiento de diabetes | |
AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
CO6150149A2 (es) | Compuestos azabiciclicos como inhibidfores de la recaptacion de monoaminas | |
PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
AR078632A1 (es) | Compuestos esteroidales modificadores de la melanogenesis y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |